AI Article Synopsis
- - Influenza and Respiratory Syncytial Virus (RSV) are major contributors to serious respiratory infections, but no approved vaccine exists for RSV, while yearly flu vaccines are required for influenza protection.
- - A new approach involves creating bivalent vaccines that target both influenza A and RSV using conserved viral sequences, either as a combined chimeric antigen or as separate antigens.
- - These bivalent vaccines showed effectiveness in animal studies, providing significant protection against both viruses, with ongoing research to understand their protective mechanisms.
Article Abstract
Influenza and Respiratory Syncytial virus (RSV) infections together contribute significantly to the burden of acute lower respiratory tract infections. Despite the disease burden, no approved RSV vaccine is available. While approved vaccines are available for influenza, seasonal vaccination is required to maintain protection. In addition to both being respiratory viruses, they follow a common seasonality, which warrants the necessity for a concerted vaccination approach. Here, we designed bivalent vaccines by utilizing highly conserved sequences, targeting both influenza A and RSV, as either a chimeric antigen or individual antigens separated by a ribosome skipping sequence. These vaccines were found to be effective in protecting the animals from challenge by either virus, with mechanisms of protection being substantially interrogated in this communication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171128 | PMC |
| http://dx.doi.org/10.1080/22221751.2023.2192821 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!